GlassScriptPhysician profile
Raj P Singh
NPI 1164546719
$1,367.47
in general payments reported to CMS, 2019-2025
26 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.48 · 2021: $21.87 · 2022: $30.39 · 2023: $442 · 2024: $395 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $287.14 | 2023 | Puraply |
| Viiv Healthcare Company | $178.84 | 2023-2025 | Apretude |
| Amgen INC. | $167.17 | 2024-2025 | Otezla, Repatha, Otezla |
| Gilead Sciences, INC. | $153.27 | 2024-2025 | |
| Intra-Sana Laboratories | $77.87 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Antares Pharma, INC. | $74.92 | 2024-2025 | Xyosted |
| Horizon Therapeutics Plc | $67.58 | 2023 | Krystexxa |
| Abbvie INC. | $65.67 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $56.44 | 2023-2025 | |
| Lucid Diagnostics INC. | $39.49 | 2022-2024 | |
| Travere Therapeutics, INC. | $38.29 | 2025 | |
| Pfizer INC. | $25.07 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $23.48 | 2019 | |
| Astellas Pharma US INC | $23.26 | 2024 | Veozah |
| Boston Scientific Corporation | $21.87 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.50 | 2025 | Injectafer |
| Apellis Pharmaceuticals, INC. | $18.43 | 2025 | Empaveli |
| Astrazeneca Pharmaceuticals LP | $15.57 | 2022 | |
| Nxstage Medical, INC. | $13.61 | 2023 | Nxstage System One, Nxstage Cartridge Express |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.